-
1.发明公开公开(公告)号：US20230148226A1
公开(公告)日：2023-05-11
申请号：US17976040
申请日：2022-10-28
Applicant: The Texas A&M University System
Inventor： Mansoor Khan , Ziyaur Rahman , Indra K. Reddy , Satish Dharani
IPC: A61K31/4985 , A61K47/02 , A61K47/10 , A61K45/06
CPC classification number: A61K31/4985 , A61K47/02 , A61K47/10 , A61K45/06
Abstract: In an embodiment, the present disclosure pertains to a stable formulation of a varenicline salt or base form containing composition that prevents or reduces formation of a nitroso impurity until the end of stated expiration or longer. In some embodiments, the composition includes varenicline and at least one pharmaceutical excipient. In some embodiments, the at least one pharmaceutical excipient includes a magnesium salt and at least one of dicalcium phosphate, polyethylene glycol, or polyethylene oxide. In some embodiments, the magnesium salt can include, without limitation, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium sulfate, magnesium trisilicate, and combinations thereof. In some embodiments, a weight ratio of the varenicline to the at least one pharmaceutical excipient ranges from 1 to 99 to 99 to 1% w/w. In some embodiments, the at least one pharmaceutical excipient is a protective pharmaceutical ingredient.
-
公开(公告)号：US20230133326A1
公开(公告)日：2023-05-04
申请号：US17975595
申请日：2022-10-27
Applicant: The Texas A&M University System
Inventor： Mansoor Khan , Ziyaur Rahman , Indra K. Reddy , Satish Dharani
Abstract: In an embodiment, the present disclosure pertains to a stable formulation of a primary, secondary, and/or tertiary amino group containing composition that prevents or reduces formation of a nitroso impurity until the end of stated expiration or longer. In some embodiments, the composition includes metformin and at least one pharmaceutical excipient. In some embodiments, the at least one pharmaceutical excipient includes a magnesium salt and at least one of a calcium salt, dicalcium phosphate, polyethylene glycol, or polyethylene oxide. In some embodiments, the magnesium salt can include, without limitation, magnesium aluminum silicate, magnesium aluminometasilicate, magnesium carbonate, magnesium oxide, magnesium silicate, magnesium stearate, magnesium sulfate, magnesium trisilicate, and combinations thereof. In some embodiments, a weight ratio of the drug to the at least one pharmaceutical excipient ranges from 1 to 99 to 99 to 1% w/w. In some embodiments, the at least one pharmaceutical excipient is a protective pharmaceutical ingredient.
-
3.发明申请公开(公告)号：US20220183994A1
公开(公告)日：2022-06-16
申请号：US17600837
申请日：2020-04-03
Applicant: The Texas A&M University System
Inventor： Carolyn L. Cannon , Kush Shah , Bhagath Chirra , Qingquan Chen , Mansoor Khan , Hung-Jen Wu
IPC: A61K9/70 , A61K33/38 , A61K31/197 , A61K31/375 , A61K31/4045 , A61K31/192
Abstract: In an embodiment, a drug delivery system and method of use thereof to treat inflammation and bacterial pathogens including multi-drug resistant pathogens, such as MDR-Pseudomonas aeruginosa, or reactive oxygen species in a subject is provided. In some embodiments, the drug delivery system includes a polymeric material, an excepient, an antioxidant agent, and an anti-inflammatory and antimicrobial agent. In some embodiments, the anti-inflammatory and antimicrobial agent is a salt of an anti-inflammatory agent and an antimicrobial agent formulated to provide a combination of antimicrobial and anti-inflammatory action from a single molecule. In some embodiments, the combined anti-inflammatory and antimicrobial agent is a silver salt of ibuprofen. In other embodiments, the combined anti-inflammatory and antimicrobial agent is unmodified, native ibuprofen.
-
-
Search Results
3
records
(took 0.016 seconds)
